[A22-99] Nivolumab (oesophageal carcinoma, combination with ipilimumab) – Addendum to Commission A22-55
Last updated 20.10.2022
Project no.:
A22-99
Commission:
Commission awarded on 06.09.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%; first-line treatment; combination with ipilimumab
After addendum now indication of major added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-55 | Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-10-20 A G-BA decision was published.